CN111954681B - 抗叶酸受体1抗体及其用途 - Google Patents

抗叶酸受体1抗体及其用途 Download PDF

Info

Publication number
CN111954681B
CN111954681B CN201980019246.4A CN201980019246A CN111954681B CN 111954681 B CN111954681 B CN 111954681B CN 201980019246 A CN201980019246 A CN 201980019246A CN 111954681 B CN111954681 B CN 111954681B
Authority
CN
China
Prior art keywords
ser
seq
gly
polypeptide sequence
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980019246.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN111954681A (zh
Inventor
王明晗
邹晖
贾海群
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dongguan Fanshi Biomedical Co ltd
Original Assignee
Dongguan Fanshi Biomedical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dongguan Fanshi Biomedical Co ltd filed Critical Dongguan Fanshi Biomedical Co ltd
Priority to CN202211567226.0A priority Critical patent/CN115925952A/zh
Publication of CN111954681A publication Critical patent/CN111954681A/zh
Application granted granted Critical
Publication of CN111954681B publication Critical patent/CN111954681B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980019246.4A 2018-03-13 2019-03-07 抗叶酸受体1抗体及其用途 Active CN111954681B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211567226.0A CN115925952A (zh) 2018-03-13 2019-03-07 抗叶酸受体1抗体及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862642213P 2018-03-13 2018-03-13
US62/642,213 2018-03-13
PCT/US2019/021084 WO2019177854A1 (en) 2018-03-13 2019-03-07 Anti-folate receptor 1 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211567226.0A Division CN115925952A (zh) 2018-03-13 2019-03-07 抗叶酸受体1抗体及其用途

Publications (2)

Publication Number Publication Date
CN111954681A CN111954681A (zh) 2020-11-17
CN111954681B true CN111954681B (zh) 2022-12-06

Family

ID=67906883

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980019246.4A Active CN111954681B (zh) 2018-03-13 2019-03-07 抗叶酸受体1抗体及其用途
CN202211567226.0A Pending CN115925952A (zh) 2018-03-13 2019-03-07 抗叶酸受体1抗体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202211567226.0A Pending CN115925952A (zh) 2018-03-13 2019-03-07 抗叶酸受体1抗体及其用途

Country Status (13)

Country Link
US (1) US11873335B2 (https=)
EP (1) EP3765521A4 (https=)
JP (2) JP7433236B2 (https=)
KR (1) KR102808710B1 (https=)
CN (2) CN111954681B (https=)
AU (1) AU2019236091B2 (https=)
BR (1) BR112020016469A2 (https=)
CA (1) CA3091683A1 (https=)
EA (1) EA202092125A1 (https=)
IL (1) IL276949A (https=)
MX (1) MX2020009522A (https=)
SG (1) SG11202007494TA (https=)
WO (1) WO2019177854A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102275930B1 (ko) * 2018-03-14 2021-07-12 (주)알테오젠 Folr1에 특이적으로 결합하는 항체 및 그의 용도
CA3160436A1 (en) * 2019-12-17 2021-06-24 Jack Chongyang LI Bispecific antibodies with alternatively matched interchain cysteines and uses thereof
TW202233684A (zh) * 2020-11-18 2022-09-01 美商泰尼歐生物公司 結合於葉酸受體α之重鏈抗體
CN115491358B (zh) * 2021-06-17 2024-09-06 复星凯特生物科技有限公司 一种靶向b7-h3和folr1双打靶点car t的制备及应用
CN116462768B (zh) * 2023-06-13 2023-09-22 浙江时迈药业有限公司 针对folr1的双特异性抗体及其用途
WO2025140416A1 (zh) * 2023-12-28 2025-07-03 上海宏成药业有限公司 抗folr1特异性抗体的发明及应用
WO2025161939A1 (en) * 2024-01-31 2025-08-07 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Antibodies and uses thereof
CN118344485B (zh) * 2024-06-18 2024-10-15 南京欧凯生物科技有限公司 抗叶酸及其结合蛋白复合物的单克隆抗体或其抗原结合片段、其制备方法及应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103037900A (zh) * 2010-02-24 2013-04-10 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
CN103687618A (zh) * 2010-11-05 2014-03-26 莫福特克公司 叶酸受体α作为用于表达叶酸受体α的癌症的诊断和预后标记
CN103747802A (zh) * 2011-04-01 2014-04-23 伊缪诺金公司 用于增加folr1癌症治疗的功效的方法
CN105814079A (zh) * 2013-08-30 2016-07-27 伊缪诺金公司 用于检测叶酸受体1的抗体和测定
CN107074955A (zh) * 2014-11-20 2017-08-18 豪夫迈·罗氏有限公司 针对FolR1和CD3的T细胞活化性双特异性抗原结合分子
CN107206072A (zh) * 2014-11-20 2017-09-26 豪夫迈·罗氏有限公司 T细胞活化性双特异性抗原结合分子CD3 ABD叶酸受体1(FolR1)和PD‑1轴结合拮抗剂的组合疗法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101034A1 (en) 2004-02-12 2016-12-07 Morphotek, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
CA2607444C (en) 2005-04-22 2015-03-10 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
EP1900752A1 (en) 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
JP5059119B2 (ja) * 2006-12-14 2012-10-24 シェーリング コーポレイション 操作された抗ｔｓｌｐ抗体
WO2008145136A1 (en) 2007-05-30 2008-12-04 Aarhus Universitet Stat3 inactivation by inhibition of the folate receptor pathway
FR2929946B1 (fr) * 2008-04-11 2010-05-28 Pf Medicament Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer
US9487582B2 (en) * 2010-01-08 2016-11-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for treating pancreatic cancer
CN103347537A (zh) 2010-10-20 2013-10-09 莫弗泰克股份有限公司 抗叶酸受体α抗体糖型
KR20140004174A (ko) 2011-01-18 2014-01-10 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 치료를 위한 조성물 및 방법
SI2731972T1 (en) 2011-07-15 2018-04-30 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
BR112014028306A2 (pt) 2012-05-15 2018-04-17 Morphotek, Inc. métodos para tratamento de câncer gástrico.
US9200073B2 (en) 2012-08-31 2015-12-01 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
WO2014055771A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
US9207238B2 (en) 2012-12-07 2015-12-08 Kyowa Hakko Kirin Co., Ltd. Anti-FOLR1 antibody
US9522196B2 (en) 2012-12-25 2016-12-20 Kagoshima University Antibody recognizing folate receptors α and β
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
SG11201509043RA (en) 2013-05-14 2015-12-30 Immunogen Inc Anti-folr1 immunoconjugate dosing regimens
CA2914237A1 (en) 2013-06-20 2014-12-24 Morphotek, Inc. Methods for treatment of ovarian cancer
PL3055332T3 (pl) 2013-10-08 2020-02-28 Immunogen, Inc. Schematy dawkowania immunokoniugatu anty-FOLR1
KR20160088930A (ko) 2013-12-04 2016-07-26 이뮤노젠 아이엔씨 항체 생산용 조성물 및 항체 생성 방법
US9950077B2 (en) 2014-06-20 2018-04-24 Bioalliance C.V. Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof
KR102508023B1 (ko) 2014-09-03 2023-03-10 이뮤노젠 아이엔씨 세포-결합제 및 세포독성 약물을 포함하는 콘주게이트
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3283886B1 (en) 2015-04-17 2020-01-15 Eisai Inc. Methods for treating lung cancer
CN116440279B (zh) 2015-09-17 2026-02-24 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
EP3526254A1 (en) 2016-10-12 2019-08-21 Sutro Biopharma, Inc. Anti-folate receptor antibodies, compositions comprising anti-folate receptor antibodies and methods of making and using anti-folate receptor antibodies
EP3544999A1 (en) 2016-11-23 2019-10-02 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
US20180333503A1 (en) 2017-05-16 2018-11-22 Immunogen, Inc. Anti-folr1 immunoconjugates and anti-pd-1 antibody combinations

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103037900A (zh) * 2010-02-24 2013-04-10 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
CN105777907A (zh) * 2010-02-24 2016-07-20 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
CN103687618A (zh) * 2010-11-05 2014-03-26 莫福特克公司 叶酸受体α作为用于表达叶酸受体α的癌症的诊断和预后标记
CN103747802A (zh) * 2011-04-01 2014-04-23 伊缪诺金公司 用于增加folr1癌症治疗的功效的方法
CN105814079A (zh) * 2013-08-30 2016-07-27 伊缪诺金公司 用于检测叶酸受体1的抗体和测定
CN107074955A (zh) * 2014-11-20 2017-08-18 豪夫迈·罗氏有限公司 针对FolR1和CD3的T细胞活化性双特异性抗原结合分子
CN107206072A (zh) * 2014-11-20 2017-09-26 豪夫迈·罗氏有限公司 T细胞活化性双特异性抗原结合分子CD3 ABD叶酸受体1(FolR1)和PD‑1轴结合拮抗剂的组合疗法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors;necela等;《PLOS ONE》;20150327;第10卷(第3期);第1-19页 *
The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity;Lin等;《Cancer Biology & Therapy》;20130828;第14卷(第11期);第1032-1038页 *

Also Published As

Publication number Publication date
AU2019236091B2 (en) 2025-06-05
JP2024056787A (ja) 2024-04-23
CA3091683A1 (en) 2019-09-19
CN115925952A (zh) 2023-04-07
WO2019177854A1 (en) 2019-09-19
EP3765521A1 (en) 2021-01-20
CN111954681A (zh) 2020-11-17
KR102808710B1 (ko) 2025-05-15
US20210002363A1 (en) 2021-01-07
JP2021517459A (ja) 2021-07-26
IL276949A (en) 2020-10-29
SG11202007494TA (en) 2020-09-29
JP7433236B2 (ja) 2024-02-19
US11873335B2 (en) 2024-01-16
EP3765521A4 (en) 2022-03-23
BR112020016469A2 (pt) 2020-12-15
MX2020009522A (es) 2020-10-22
EA202092125A1 (ru) 2020-12-15
AU2019236091A1 (en) 2020-09-03
KR20200132900A (ko) 2020-11-25

Similar Documents

Publication Publication Date Title
JP7262440B2 (ja) 抗ｃｄ４７抗体及びその使用
CN111954681B (zh) 抗叶酸受体1抗体及其用途
CN111836644A (zh) 抗密蛋白18.2抗体及其用途
JP7455388B2 (ja) 抗ｄｌｌ３抗体及びその使用
CN111867628A (zh) 抗cd73抗体及其用途
JP2021500916A (ja) 抗ｔｉｍ−３抗体及びその使用
US20200399396A1 (en) Anti-tip-1 antibodies and uses thereof
HK40090440A (zh) 抗叶酸受体1抗体及其用途
HK40033064B (en) Anti-folate receptor 1 antibodies and uses thereof
HK40033064A (en) Anti-folate receptor 1 antibodies and uses thereof
HK40119299A (zh) 抗cd73抗体及其用途
HK40110312A (zh) 抗dll3抗体及其用途
HK40031476A (en) Anti-claudin 18.2 antibodies and uses thereof
EA046422B1 (ru) Антитела против рецептора фолата 1 и их применения
HK40039992B (zh) 抗dll3抗体及其用途
HK40039992A (en) Anti-dll3 antibodies and uses thereof
HK40031477B (zh) 抗cd73抗体及其用途
HK40031477A (en) Anti-cd73 antibodies and uses thereof
EA043281B1 (ru) Анти-cd47 антитела и их применение
HK40018997B (zh) 抗cd47抗体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40033064

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant